Literature DB >> 16902418

Population-based assessment of non-melanoma cancer risk in relatives of cutaneous melanoma probands.

April A Larson1, Sancy A Leachman, Mark J Eliason, Lisa A Cannon-Albright.   

Abstract

Using the unique Utah Population Database, which links Utah genealogical data with Utah cancer data, we examined risks for other cancers among relatives of 4,079 melanoma cases. Age- and sex-specific rates for 35 different cancer sites were calculated, and used to estimate relative risks among relatives. In addition to the well-recognized risk for melanoma among first-degree relatives, we found significantly increased risks for prostate, breast, and colon cancers, non-Hodgkin's lymphoma, and multiple myeloma, ranging from 32 to 72% increased risk. Among second-degree relatives, in addition to increased risk for melanoma, we identified significantly increased risks for prostate cancer and multiple myeloma (27 and 53% increase, respectively). Among first-degree relatives of melanoma cases diagnosed before the age of 40 years, we found significantly elevated risks for cutaneous melanoma (380% increase) and prostate cancer (83% increase). Significantly increased risks for prostate cancer and multiple myeloma in both first- and second-degree relatives of melanoma cases are suggestive of heritable cancer syndromes. The increased risks for five additional cancer types in first-degree relatives of melanoma cases suggest that individuals with a family history of melanoma should strictly adhere to recommended screenings for all cancers.

Entities:  

Mesh:

Year:  2006        PMID: 16902418     DOI: 10.1038/sj.jid.5700507

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  12 in total

1.  Prostate cancer risk alleles and their associations with other malignancies.

Authors:  Phillip R Cooper; Barry B McGuire; Brian T Helfand; Stacy Loeb; Qiaoyan Hu; William J Catalona
Journal:  Urology       Date:  2011-08-05       Impact factor: 2.649

2.  Increased incidence of bladder cancer, lymphoid leukaemia, and myeloma in a cohort of Queensland melanoma families.

Authors:  Jazlyn Read; Judith Symmons; Jane M Palmer; Grant W Montgomery; Nicholas G Martin; Nicholas K Hayward
Journal:  Fam Cancer       Date:  2016-10       Impact factor: 2.375

Review 3.  Barriers to risk-understanding and risk-reduction behaviors among individuals with a family history of melanoma.

Authors:  Laura Fitzpatrick; Jennifer L Hay
Journal:  Melanoma Manag       Date:  2014-12-04

Review 4.  State of melanoma: an historic overview of a field in transition.

Authors:  Vikram C Gorantla; John M Kirkwood
Journal:  Hematol Oncol Clin North Am       Date:  2014-06       Impact factor: 3.722

5.  Melanoma risk assessment based on relatives' age at diagnosis.

Authors:  Yelena P Wu; Wendy Kohlmann; Karen Curtin; Zhe Yu; Heidi A Hanson; Mia Hashibe; Bridget G Parsons; Jathine Wong; Joshua D Schiffman; Douglas Grossman; Sancy A Leachman
Journal:  Cancer Causes Control       Date:  2017-12-14       Impact factor: 2.506

6.  Low accuracy of self-reported family history of melanoma in high-risk patients.

Authors:  Nicholas D Flint; Michael D Bishop; Tristan C Smart; Jennifer L Strunck; Kenneth M Boucher; Douglas Grossman; Aaron M Secrest
Journal:  Fam Cancer       Date:  2021-01       Impact factor: 2.375

7.  Effect of a detailed family history of melanoma on risk for other tumors: a cohort study based on the nationwide Swedish Family-Cancer Database.

Authors:  Tianhui Chen; Mahdi Fallah; Elham Kharazmi; Jianguang Ji; Kristina Sundquist; Kari Hemminki
Journal:  J Invest Dermatol       Date:  2013-11-05       Impact factor: 8.551

8.  Family history of cancer and malignant germ cell tumors in children: a report from the Children's Oncology Group.

Authors:  Jenny N Poynter; Amy H Radzom; Logan G Spector; Susan Puumala; Leslie L Robison; Zhi Chen; Julie A Ross; Xiao-Ou Shu
Journal:  Cancer Causes Control       Date:  2009-10-15       Impact factor: 2.506

9.  CtBP1 is expressed in melanoma and represses the transcription of p16INK4a and Brca1.

Authors:  Hui Deng; Jing Liu; Yu Deng; Gangwen Han; Yiqun G Shellman; Steven E Robinson; John J Tentler; William A Robinson; David A Norris; Xiao-Jing Wang; Qinghong Zhang
Journal:  J Invest Dermatol       Date:  2013-01-10       Impact factor: 8.551

10.  A population-based analysis of clustering identifies a strong genetic contribution to lethal prostate cancer.

Authors:  Quentin Nelson; Neeraj Agarwal; Robert Stephenson; Lisa A Cannon-Albright
Journal:  Front Genet       Date:  2013-08-20       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.